OCS Key Statistics, Chart & Performance
The current stock price of OCS is 21.68 USD. In the past month the price increased by 11.7%. In the past year, price increased by 31.95%.
OCS Latest News, Press Relases and Analysis
OCS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.94 | 955.13B | ||
| JNJ | JOHNSON & JOHNSON | 19.45 | 486.51B | ||
| MRK | MERCK & CO. INC. | 11.32 | 247.51B | ||
| PFE | PFIZER INC | 8.13 | 148.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.95 | 106.16B | ||
| ZTS | ZOETIS INC | 18.71 | 52.29B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.67 | 22.93B | ||
| VTRS | VIATRIS INC | 4.69 | 12.59B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.81 | 10.88B | ||
| CORT | CORCEPT THERAPEUTICS INC | 97.85 | 9.06B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.52B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.23B |
Related stock screener links
About OCS
Company Profile
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The company is headquartered in Zug, Zug and currently employs 49 full-time employees. The company went IPO on 2023-03-03. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Company Info
OCULIS HOLDING AG
Bahnhofstrasse 20
Zug ZUG CH
Employees: 49
Phone: 41417113960
OCULIS HOLDING AG / OCS FAQ
Can you describe the business of OCULIS HOLDING AG?
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The company is headquartered in Zug, Zug and currently employs 49 full-time employees. The company went IPO on 2023-03-03. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
What is the current price of OCS stock?
The current stock price of OCS is 21.68 USD. The price increased by 10.05% in the last trading session.
What is the dividend status of OCULIS HOLDING AG?
OCS does not pay a dividend.
What is the ChartMill technical and fundamental rating of OCS stock?
OCS has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about OCULIS HOLDING AG (OCS) stock?
13 analysts have analysed OCS and the average price target is 44.99 USD. This implies a price increase of 107.53% is expected in the next year compared to the current price of 21.68.
Is OCULIS HOLDING AG (OCS) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on OCS.
What is the expected growth for OCS stock?
The Revenue of OCULIS HOLDING AG (OCS) is expected to decline by -2.94% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
OCS Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to OCS. When comparing the yearly performance of all stocks, OCS is one of the better performing stocks in the market, outperforming 88.77% of all stocks.
OCS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OCS. While OCS seems to be doing ok healthwise, there are quite some concerns on its profitability.
OCS Financial Highlights
Over the last trailing twelve months OCS reported a non-GAAP Earnings per Share(EPS) of -2.7. The EPS decreased by -22.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -62.02% | ||
| ROE | -79.71% | ||
| Debt/Equity | 0.02 |
OCS Forecast & Estimates
13 analysts have analysed OCS and the average price target is 44.99 USD. This implies a price increase of 107.53% is expected in the next year compared to the current price of 21.68.
For the next year, analysts expect an EPS growth of 10.69% and a revenue growth -2.94% for OCS